@article{HenryNeillBeckeretal.2015, author = {Henry, Brian D. and Neill, Daniel R. and Becker, Katrin Anne and Gore, Suzanna and Bricio-Moreno, Laura and Ziobro, Regan and Edwards, Michael J. and Muehlemann, Kathrin and Steinmann, Joerg and Kleuser, Burkhard and Japtok, Lukasz and Luginbuehl, Miriam and Wolfmeier, Heidi and Scherag, Andre and Gulbins, Erich and Kadioglu, Aras and Draeger, Annette and Babiychuk, Eduard B.}, title = {Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice}, series = {Nature biotechnology : the science and business of biotechnology}, volume = {33}, journal = {Nature biotechnology : the science and business of biotechnology}, number = {1}, publisher = {Nature Publ. Group}, address = {New York}, issn = {1087-0156}, doi = {10.1038/nbt.3037}, pages = {81 -- U295}, year = {2015}, abstract = {Gram-positive bacterial pathogens that secrete cytotoxic pore-forming toxins, such as Staphylococcus aureus and Streptococcus pneumoniae, cause a substantial burden of disease. Inspired by the principles that govern natural toxin-host interactions, we have engineered artificial liposomes that are tailored to effectively compete with host cells for toxin binding. Liposome-bound toxins are unable to lyse mammalian cells in vitro. We use these artificial liposomes as decoy targets to sequester bacterial toxins that are produced during active infection in vivo. Administration of artificial liposomes within 10 h after infection rescues mice from septicemia caused by S. aureus and S. pneumoniae, whereas untreated mice die within 24-33 h. Furthermore, liposomes protect mice against invasive pneumococcal pneumonia. Composed exclusively of naturally occurring lipids, tailored liposomes are not bactericidal and could be used therapeutically either alone or in conjunction with antibiotics to combat bacterial infections and to minimize toxin-induced tissue damage that occurs during bacterial clearance.}, language = {en} }